Deals channel feed – Endpoints News

Deals channel feed

PureTech, Nektar put an end to deal discussions, citing too much 'uncertainty'

3 years ago

Ginkgo inks $144M deal with Merck to engineer enzymes to improve ingredient manufacturing

3 years ago

Attractive M&A options? Analysts break down what's hot right now

3 years ago

BioNTech allies with Australian state, initializing plans to construct new R&D and manufacturing facilities

3 years ago

An AI, err machine learning, shop lines up Eli Lilly as partner ahead of first in-house clinical trial

3 years ago

Rising from the IL-2 ashes and drastic reorg, Nektar in merger talks with PureTech

3 years ago

Advocacy group and former antitrust official look to comment on Illumina's controversial Grail merger

3 years ago

With FDA decision one month away, Provention partners with Sanofi on US marketing for type 1 diabetes drug

3 years ago

In add-on to eye disease pipeline, Boehringer pays Surrozen to acquire rights to Wnt drug

3 years ago

AstraZeneca taps two more targets from its AI partner, again in CKD and IPF

3 years ago

CNS-focused gene therapy biotech forges manufacturing deal for hearing loss drug

3 years ago

Biotech billionaire Bob Duggan flies the white flag as Summit hunts a new owner, or partner, for sole clinical-stage effort

3 years ago

Paul Hudson and TrialSpark's mutual desire to speed up development converges in three-year, six-drug goal

3 years ago

Looking to push CAR-T in solid tumors, Bay Area biotech goes public in SPAC flip — with slight name change

3 years ago

After 12 months of digging, Pfizer opts for one of two Voyager capsids for gene therapy

3 years ago

In post-Covid life, Vir looks to stomp out influenza in up to $1B BARDA contract that boosts GSK-allied mAb

3 years ago

Bristol Myers inks protein degrader deal via Celgene team's link to seed-stage biotech

3 years ago

Sanofi licenses a preclinical genetic disease drug from an unknown biotech spun out of the NIH

3 years ago

Can a smartphone app detect Covid? Pfizer throws down $116M to find out

3 years ago

Updated: AstraZeneca nabs a small rare disease gene therapy player for 667% premium

3 years ago

Myovant board balks as majority owner Sumitomo swoops in with a $2.5B deal to buy them out

3 years ago

Incyte pays out $70M to get hands on Medicxi-backed vitiligo biotech

3 years ago

AmplifyBio scoops up lab space and other assets from PACT Pharma as cell therapy biotech readjusts

3 years ago

Solid Bio gets a new CEO, $75M cash and drops lead drug as big investors jury-rig a merger deal

3 years ago

First page Previous page 50 51 525354 55 56 Next page Last page